

## **Biochanin A: A Novel Bioactive Multifunctional Compound from Nature**

**Ayesha Sarfraz<sup>1#</sup>, Maria Javeed<sup>1#</sup>, Muhammad Ajmal Shah<sup>2</sup>, Ghulam Hussain<sup>3</sup>, Nusrat Shafiq<sup>4</sup>, Iqra Sarfraz<sup>1</sup>, Ammara Riaz<sup>1</sup>, Ayesha Sadiqa<sup>1</sup>, Rabia Zara<sup>1</sup>, Saba Zafar<sup>1</sup>, Lubna Kanwal<sup>5</sup>, Satyajit D. Sarker<sup>6</sup>, Azhar Rasul<sup>1,\*</sup>**

<sup>1</sup>Department of Zoology, Faculty of Life Sciences, Government College University, Faisalabad, 38000 Pakistan

<sup>2</sup>Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, 38000 Pakistan

<sup>3</sup>Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, 38000 Pakistan

<sup>4</sup>Department of Chemistry, Government College Woman University Faisalabad (GCWUF), 38000 Faisalabad, Pakistan

<sup>5</sup>Institute of Pure and Applied Zoology, University of Okara, Okara, Pakistan

<sup>6</sup>School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, England, UK

<sup>#</sup>Authors who contributed equally in publication

### **\*Corresponding authors**

Dr. Azhar Rasul, Assistant Professor, Cell and Molecular Biology Lab, Department of Zoology, Government College University, Faisalabad, 38000 Pakistan.

Tel: +92 3218409546, E-mail: [drazharrasul@gmail.com](mailto:drazharrasul@gmail.com)

## **Abstract**

Natural products (NPs) will continue to serve humans as matchless source of novel drug leads and inspiration for the synthesis of non-natural drugs. As our scientific understanding of 'nature' is rapidly expanding, it would be worthwhile to illuminate the pharmacological distinctions of NPs to the scientific community and public. Flavonoids have long fascinated scientists with their remarkable structural diversity as well as biological functions. Consequently, this review aims to shed light on the sources and pharmacological significance of a dietary isoflavone, biochanin A, which has been recently emerged as multitargeted and multifunctional guardian of human health. Biochanin A possesses anti-inflammatory, anticancer, neuroprotective, antioxidant, anti-microbial, and hepatoprotective properties. This anticancer isoflavone combat cancer development by inducing apoptosis, inhibition of metastasis and arresting cell cycle via targeting several deregulated signaling pathways of cancer. It fights inflammation by blocking the expression and activity of pro-inflammatory cytokines via modulation of NF- $\kappa$ B and MAPKs. Biochanin A acts as a neuroprotective agent by inhibiting microglial activation and apoptosis of neurons. As biochanin A has potential to modulate several biological networks, thus, we anticipate that this therapeutically potent compound might serve as novel lead for drug development in the near future.

**Key words:** Biochanin A, isoflavone, anticancer, anti-inflammatory, antioxidant, neuroprotective, anti-microbial

## ***1. Introduction***

It is no more mystic that over the centuries, human pharmaceutic armamentarium is remarkably indebted to natural products (NPs) [1]. NPs predominate as an endless source of novel scaffolds for developing effective drugs to cure numerous pathological conditions. In spite of the emerging synthetic chemistry-based approaches in pharmaceuticals, the contribution of NPs for the prevention as well as cure of diseases is still enormous [2]. NPs have been reported as the richest source of novel mediators of biomolecular functions [3] which have improved human health by serving as useful drugs of choice [4]. To date, NPs and their derived compounds account for approximately 50% of anti-infective and 50% of anticancer drugs [5] such as paclitaxel, silibinin, and lovastatin which are all nature-inspired drugs [6]. Eighty percent of the human populations still depend on plant-derived drugs to meet their healthcare demands [7]. NPs exhibit various pharmacological activities such as anticancer [8], anti-inflammatory [9], antioxidant [10], and anti-microbial [11].

NPs are categorized on the basis of their structural similarities into following major classes: polyphenols (flavonoids, tannins, lignins) alkaloids, terpenoids, and saponins [12]. Isoflavones, a subclass of flavonoids, are phytoestrogens that have similarity to 17- $\beta$ -estradiol in chemical composition. Isoflavones are mainly found in the plants of legume family such as soybeans, peanuts, chickpeas and green beans. Isoflavones-rich diets have attracted attention of scientific community because of their health advantages such as chemoprevention, anti-osteoporosis and maintenance of cognitive functions [13].

Biochanin A (4'-methoxy-5, 7-dihydroxy isoflavone) is a naturally occurring isoflavone isolated from red clover, soy, chickpea, and many other plants [14, 15]. Pharmacological and biological activities of biochanin A are well-documented as anticancer [16], anti-inflammatory [17], antioxidant [18], neuroprotective [19], anti-microbial [20], and hepatoprotective [21].

This review article aims to highlight the researches related to biological and pharmacological efficacy of biochanin A which will hopefully pave a way for scientific community for further research on biochanin A. The literature was assessed via various e-sites such as PubMed, Scopus, Science Direct, and Elsevier. Key words utilized for searching data are “biochanin A”, “natural products”, “antioxidant”, “neuroprotective”, “anti-inflammatory”, and “anticancer”.

## 2. Natural sources of biochanin A

Biochanin A ( $C_{16}H_{12}O_5$ ) was firstly isolated from the leaves and stems of *Trifolium pratense* L., of family Leguminosae. *T. pratense* is utilized on large scale to relieve postmenopausal problems in women and to cure asthma, eczema, cough, and eye disorders [22, 23]. Further, biochanin A was also isolated from *Astragalus membranaceus*, which is a traditionally used medicine in China [24]. Some other natural sources of biochanin A include soy (*Glycine max*) [25, 26], peanuts (*Arachis hypogaea*) [27], chickpea (*Cicer arietinum*) [28], Indian rosewood (*Dalbergia sissoo*), [29], golden tree (*Cassia fistula*) [20], and alfalfa sprouts (*Medicago sativa*) [30, 31] (Figure 1). Yield of biochanin A was recorded as 1.79–3.32 mg g<sup>-1</sup> from dry leave matter of *T. pratense* [32]. 5mg of biochanin A was isolated from 20 mg chloroform fraction of *D. sissoo* leave extract [33]. Comparison of yield of isoflavones from chickpea shows that biochanin A is most abundant isoflavone with highest yield of 15.7 mg/150 mg among other isoflavones. As chickpea is a common dietary food, thus, biochanin A is an easily available and cost-effective pharmacologically active compound [34]. Biochanin A was isolated at the concentration of 0.133 mg/ 100 g of hexane-defatted dry matter of *A. hypogaea* [35] The major sources of biochanin A are summarized in Table 1.

**Table 1.** Natural sources of biochanin A

Plant Name	Common Name	Part Used	Fraction	Yield of Biochanin	Functions	References
<i>Cicer arietinum</i>	Chickpea	Seeds and sprout	n-hexane, ethyl acetate	15.7 mg/150mg	Anticancer, anti-obesity	[34]
<i>Trifolium pratense</i>	Red clover	Above ground parts, flower heads	---	0.07–0.33% Above ground parts, 0.070–0.14% flower heads	Anti-proliferative	[36]
<i>Casia fistula</i>	Amaltas	Fruit	Dichloro-methane	---	Anticancer, antiviral, Anti-inflammatory	[20]
<i>Dalbergia paniculata</i>	Phansi	Stem, bark and leaves	Chloroform	---	Antimicrobial, antioxidant, anti-inflammatory, anti-diarrheal	[37]
<i>Arachis hypogaea</i>	Peanut	Peanut skin	n-hexane	0.964mg/100g, 0.133mg/100g	Antiviral, anti-inflammatory, Anti-carcinogenic	[27, 35]
<i>Medicago sativa</i>	Alfalfa	Leaves	---	---	Antioxidant, anti-ulcer, neuroprotective	[38, 39]
<i>Astragalus membranaceus</i>	Goat's horn	Roots	Acetonitrile,	0.006 mg/g	Anti-tumor, antioxidant, antiviral	[40]

### **3. Pharmacological activities of biochanin A**

A natural bioactive compound “biochanin A” has been well-known for its wide range of pharmacological traits (Figure 2). Various *in vitro* as well as *in vivo* studies on biochanin A have reported its bioactivities and associated mechanisms of actions.

#### **3.1 Anticancer activity**

Cancer is a hyperproliferative disorder which is second leading cause of mortalities around the globe. Existing chemotherapeutic drugs for cancer have delimited clinical applications due to their non-selectivity and cytotoxic effects towards normal cells. These shortcomings provoke the need for the development of agents with improved pharmacological profiles against cancer [41]. Natural compounds such as flavonoids, phenolic compounds and glycosides are reported to suppress proliferation and halt metastatic capabilities of cancer cells [42]. NPs proved to be efficacious lead structure for the discovery of anti-cancer agents because of low toxicity profiles, adequacy of activity, biosafety and common availability [43].

Biochanin A, an isoflavone, has been affirmed to mediate its anti-tumorigenic effects by prohibiting cellular growth, activating cancer cell apoptosis, blocking angiogenesis, halting metastasis, and arresting cell cycle (Figure 3) [24]. Biochanin A possesses anti-cancer properties against bladder, breast, pancreatic, prostate, osteosarcoma and liver cancers (Table 2) [44].

##### **3.1.1 Biochanin A and cell cycle arrest**

Cell cycle progression is directed by the activation of cyclin-dependent kinases (CDKs) and accumulation of cyclins [45]. Thus, targeting cell cycle regulatory proteins particularly CDKs and cyclins to halt cellular growth presents innovative approaches for drug discovery against cancer [46]. Isoflavones have been utilized as promising chemopreventive agents from several years [47], because they have potent ability to mediate the functioning of CDKs and cyclins along with various regulatory proteins of cell cycle [4].

Biochanin A has potential to arrest cell cycle at G1, G2/M and G0/G1 phases in various cancer cells. In LNCaP and PC-3 cancer cells, it induced arrest at G2/M and G0/G1 phase via enhancing p21 and reducing cyclin B expression [48, 49]. Combinatorial treatment of biochanin A and

sorafenib to HepG2 cells induced G0/G1 phase arrest and downregulated the gene expression of cyclin D, Ki-67 as well as survivin [50]. Furthermore, biochanin A mediated cell cycle arrest at G2/M phase in SW-480 colon cancer cells, S phase in A549 cells and G1 phase in U87 glioma cells via up-regulating p53 and its downstream target p21 while reducing the expression of cyclin A and CDK2 (Figure 3) [47, 51, 52].

**Table 2.** Molecular targets of biochanin A in different cancer types

Cancer type	Cell lines	Treatment condition		EC <sub>50</sub>	Molecular targets	Cell cycle arrest	References
		No. of cells/well	Treatment time				
Breast	T47D, MCF-7	4×10 <sup>3</sup>	24 h, 48 h	50 µM	ERα↑, miR-375↑, Bcl-2↓, Bax↑, HER-2↑, MMP-9, DPC4↓, p300↓, p53↑, TGFβR2↓, gadd45↓, IκBα↑, CYP19↓, iNOS↓	G2/M	[24, 53-61]
	MCF-7	5×10 <sup>5</sup> , 2×10 <sup>4</sup>	1 h, 48 h, 72 h	5 µM, 2-6 mg/kg, 25 µg/mL			
	MDA-MB-231	2×10 <sup>4</sup>	72 h	10 µM			
	SK-BR-3, MCF-7	2×10 <sup>5</sup> , 3×10 <sup>6</sup>	24 h, 72 h	2.5, 8, 12.5, 50 µM			
Glioma	C6, bEnd.3	5×10 <sup>5</sup> , 1×10 <sup>6</sup> , 2500 cells	72 h, 48 h	35 µM/L	VEGFR 2↓, HIF-1α↓, eIF4E↓, p-p53↑, p-ERK↓, EGFR↓, p-Akt↓, c-myc↓, MMP-2↓, MT1-MMP protein expression↓	G1	[15, 52, 62-64]
	U87	--	72 h	50 µM			
	U87-MG, T98 G	0.5-1×10 <sup>6</sup> , 2500, 10×10 <sup>3</sup>	72 h	50 µM, 70 µM			
	U251, U87, F98, GL261	1000-3500 cells	4 days	50 µM/L			
Lung	A549, 95D	--	24 h, 48 h	40 µM, 200 and 240 nmol/L	Akt↓, ERK1/2↓, NF-κB↓, p21↑, cyclin A↓, CDK2↓, cleaved caspase-3↑, Bcl-2↓, Bax↑	S phase	[51, 65-67]
	A427	3×10 <sup>3</sup>	24 h	40 µM			
	NCI-H460	5×10 <sup>3</sup>	24 h	1 µM			
Leukemia	AML-193	3×10 <sup>3</sup>	24 h	40 µM	--	--	[66, 68, 69]
	WEHI-3B	4×10 <sup>3</sup>	48 h	50 µM			
Prostate	LNCaP	4×10 <sup>4</sup> , 1×10 <sup>5</sup> , 5×10 <sup>4</sup>	24 h, 48 h, 6 days	50 ng/ml, 8, 13 µg/ml, 5 µM	NF-κB↓, p21↑, PLK-1↓, EGFR↓, caspase-3 <sup>Act</sup> , PCNA↓, Bax↑, Bcl-2↓, cyclin B↓, PI3K/Akt↓, p-JNK↑, p-ERK1/2↓	G2/M, G1, G0/G1	[48-50, 70-73]
	LNCaP, PC3	2×10 <sup>3</sup>	72 h	50-100 µM			
	PC3	2×10 <sup>4</sup>	24 h	8.33 µM			
Liver	Huh-7, HepG2, SNU-449	3,000 cells	72 h	40 µM (Huh-7), 22 µM (HepG2)	Bax↑, Bcl-2↓, Bcl-xL↓, caspase-9↑, caspase-3↑, Ki-67↓, cyclin D↓,	G0/G1	[50, 74]

	HepG2, Hep3B, Huh-7, HA22T	3000 cells/well, $1 \times 10^4$	3 days	0.1-1000 $\mu$ M, $26 \pm 2$ $\mu$ g/ml (HepG2), $20 \pm 2$ $\mu$ g/ml (Hep3B), $24 \pm 5$ $\mu$ g/ml (Huh-7), $15 \pm 1$ $\mu$ g/ml (PLC), $19 \pm 3$ $\mu$ g/ml (HA22T)	survivin↓		
Colon	HCT-116, SW-480	5000 cells/well	24, 48, 72 h	~50 $\mu$ M, 100 $\mu$ M	p53/21↑, P-gp expression↑	G2/M	[47, 75]
	LS-180	--	1/5 days	20 $\mu$ M			
Gastric	HSC-41E6, HSC-45M2, SH101-P4	$2 \times 10^4$	48 h	7.6 $\mu$ g/ml (HSC-41E6), 9.8 $\mu$ g/ml (HSC-45M), 10.2 $\mu$ g/ml (SH101-P4)	--	---	[76]
Pharynx	FaDu	$0.2 \times 10^5$ cells/ml	24, 48 h	25, 50 $\mu$ M	Cleaved caspase-8↑, FasL↑, PARP↑, Bcl-2↓, Bcl-xL↓, Bad↑, caspase-9↑, MMP-2/-9↓, p38MAPK↓, NF- $\kappa$ B↓	--	[77]
Melanoma	SK-Mel-28	$2 \times 10^6$ cells/ml	24, 48, 72 h	0, 10, 25, 50, 75 and 100 $\mu$ M	p-MAPKs↑	--	[78, 79]
	B16	--	48 h	22 $\mu$ M			
Pancreatic	Panc1, AsPC-1	2500 cells	72 h	70 $\mu$ M	Activation of EGFR↓, activation of Akt and MAPK↓, MMP-2↓	--	[80]
Osteosarcoma	MG-63	$2 \times 10^3$ , $5 \times 10^3$ cells/ml	6, 12, 24, and 48 h	$20 \pm 0.3$ $\mu$ g/mL, 4 and 8 $\mu$ M	PARP↑, Bcl-2↓, Bcl-xL↓, Bax↑, caspase-3/-9↑, BGLAP↓, ATF3↑, TP53↓	G0/G1	[44, 81-83]
	U2OS	--	--	10-20 $\mu$ g/mL			

Down-Regulation ↓, Up-Regulation ↑, Inhibition ⊥, B-Cell Lymphoma 2 (Bcl-2), Bcl-2-Associated X Protein (Bax), B-Cell Lymphoma-X1 (Bcl-xL), c-Jun N-Terminal Kinase (JNK), Mitogen-Activated Protein Kinase (MAPK), Nuclear Factor Kappa B (NF- $\kappa$ B), Tumor Necrosis Factor- $\alpha$  (TNF-  $\alpha$ ), Mammalian Target of Rapamycin (mTOR), Extracellular Signal-Regulated Kinase (ERK), Cytochrome c (Cyt c), Poly (ADP-Ribose) Polymerase (PARP), Matrix Metalloproteinase (MMP), Epidermal Growth Factor Receptor (EGFR), Tumor Protein (p53), Proliferating Cell Nuclear Antigen (PCNA), Interleukin (IL), Vascular Endothelial Growth Factor Receptor 2 (VEGFR 2), Inducible Nitric Oxide Synthase (iNOS), Transforming Growth Factor Beta Receptor 2 (TGF $\beta$ R2), Bone Gamma Carboxyglutamate Protein (BGLAP), Activating Transcription Factor 3 (ATF3).

### **3.1.2 Biochanin A and apoptosis**

Carcinogenesis emerges from the impairment of genes that control cellular growth and division. Thus, blocking of tumorigenesis by stimulating apoptosis in immortalized cancerous cells is an effective approach to combat cancer [84]. Apoptosis can be triggered by extrinsic or intrinsic pathways. These signaling pathways lead to caspase cascade activation [85]. Upon stimulation, initiator caspases via proteolytic cleavage trigger the activation of downstream effector caspases to induce apoptosis [86]. Thus, small bioactive molecules that trigger apoptosis are promising candidates to combat cancer [87].

Collected information by the researchers recommends that natural bioactive compounds have a potential to induce apoptosis via regulation of variety of signaling molecules [88-91]. Anticancer activity of biochanin A has been reported to be associated with inducing apoptosis via mediating the Bcl-2 family proteins, pro-inflammatory cytokines [24, 44, 50, 66, 77, 81, 82], MAPK (mitogen activated protein kinase) signaling network [p38 MAPK, JNK (c-Jun amino-terminal kinase), and ERK (extracellular signal regulated kinase)] [15, 44, 58, 73, 92], NF- $\kappa$ B (Nuclear factor kappa B) [70, 77], discharge of cytochrome c [44], and activation of caspase family members including caspase-3/-8/-9 [50, 73, 77, 81] (Figure 3).

### **3.1.3 Biochanin A and NF- $\kappa$ B signaling pathway**

NF- $\kappa$ B performs an imperative role in various biological processes such as survival, proliferation, inflammation and immune response [93]. Aberrant activation of NF- $\kappa$ B leads towards the development and progression of cancer. Hence, targeting NF- $\kappa$ B has potential to cure cancer [94].

Recently, NF- $\kappa$ B has been reported as a target for several phytochemicals including isoflavones [95]. Biochanin A halted proliferation of head and neck cancers via blocking the activation of NF- $\kappa$ B [77]. Moreover, treatment of prostate [48-50, 70-73] and lung [55, 84, 85] cancerous cells with biochanin A led to stimulation of apoptosis via dose-dependent inhibition of NF- $\kappa$ B pathway (Table 2). It can be concluded that biochanin A triggers apoptosis via inhibiting NF- $\kappa$ B but whether it directly blocks NF- $\kappa$ B pathway or by its upstream signaling pathways (STAT3, JAK) yet need to be investigated by the researchers.



Biochanin A inhibited the degradation as well as phosphorylation of I $\kappa$ B $\alpha$ , thus, blocking the activation of NF- $\kappa$ B which reduced the proliferation of HT-29 cells [16]. However, surprisingly, one study also reported the up-regulation of NF- $\kappa$ B and MAPK signaling pathway after treatment with biochanin A in SK-Mel-28 cancer cells [78]. Thus, this contradictory issue of modulation of NF- $\kappa$ B pathway by biochanin A needs to be resolved by further investigations in future.

#### **3.1.4 Biochanin A and MAPK and PI3K/Akt pathway**

The MAPK family is characterized by three members as p38MAPK, JNK, and ERK. MAPK/ERK & Akt signaling cascades have a critical role in cellular growth, migration, differentiation, and apoptosis [96, 97]. Therefore, these pathways are reported as promising therapeutic targets for cancer therapy [98].

Biochanin A blocked the activation of pro-angiogenic proteins (ERK/Akt) as well as blocked VEGF and HIF-1 $\alpha$  (Hypoxia-inducible factor 1 alpha) in glioma C6 cells [15]. It also prohibited growth and migration of FaDu cancerous cells via down-regulating MMP-2/-9 (matrix metalloproteinase-2/-9) that is mediated by reduction in p38MAPK and Akt pathways [77]. Treatment with biochanin A has inhibitory effects on the activation of MAPK/Akt which in turn reduce EGFR (endothelial growth factor receptor) expression (Figure 3) [80]. Moreover, combinatorial treatment of biochanin A and temozolomide reduced the levels of EGFR, p-ERK, p-Akt, and c-Myc in glioma (T98, U87) cells [52]

#### **3.2 Anti-inflammatory activity**

Inflammation is regarded as the usual host response to a tissue injury or a protective attempt by the organism against infections or any other stimuli. In case of chronic inflammation, a microenvironment arises in which various immune cells, stromal cells and cancer cells coexist. All of these cellular species collaborate for the production of inflammatory mediators such as growth factors and cytokines [99].

Biochanin A shows anti-inflammatory effects via inhibition of NF- $\kappa$ B and MAPK as well as the release of inflammatory mediators as TNF- $\alpha$  (tumor-necrosis factor-alpha), IL-1 $\beta$  (interleukin 1 beta), iNOS (inducible nitric oxide synthase), NO, and PGE2 (prostaglandin E2) in LPS-induced BV2 microglia cells [100]. In another study, biochanin A showed anti-inflammatory response via

up-regulating PPAR- $\gamma$  (peroxisome proliferator-activated receptor gamma), thus, reducing the activation of NF- $\kappa$ B and blocking the expression of TNF- $\alpha$ , IL-8, VCAM-1 (vascular cell adhesion protein 1) and ICAM-1 (intercellular adhesion molecule 1) in HUVEC cells [30]. Biochanin A treatment also reduced the LPS-activated expression of NO and iNOS via blocking NF- $\kappa$ B and inflammatory pathways in macrophages [16]. Biochanin A enhanced the expression of HO-1 (heme oxygenase-1) and Nrf2 (nuclear factor erythroid-2-related factor 2) in dose-mediated mode in LPS-induced acute liver injury. Moreover, biochanin A also inhibited inflammasome activation via reducing the interaction among NLRP3 and thioredoxin-interacting protein (TXNIP) (Figure 4) [101].

Biochanin A protected rat chondrocytes against IL-induced inflammation via reduction of NO synthase 2, COX-2, inflammatory cytokines, and PGE2. Besides this, biochanin A also repressed the phosphorylation of NF- $\kappa$ B, thus, protecting rat chondrocytes from inflammation (Figure 4) [102]. Biochanin A was found effective to suppress TNF- $\alpha$  and IL-6 in RAW264.7 macrophages [103]. Biochanin A blocked the expression of Solar UV (sUV)-mediated COX-2 enzyme in mouse JB6 P+ cells and human HaCaT keratinocytes [104]. Biochanin A along with phloretin attenuates the production of allergic cytokine via suppression of intracellularly produced ROS, suggesting that they may have potent anti-allergic property *in vitro* in RBL-2H3 cells [68].

### **3.3 Antioxidant activities**

In living systems, imbalance between ROS generation and antioxidant defensive systems can cause deterioration of biologically important targets, thus, causing various pathologies such as inflammation, allergies, and cardiovascular ailments. Oxidative stress is also a key contributor to neurodegeneration, aging, cancer, and diabetes [105]. Therefore, eradicating free radicals and activating the cytoprotective defense system has beneficial health effects [106].

Biochanin A has the capability to protect HepG2 liver cells against t-BHP-mediated oxidative injury by the activation of Nrf2, thereby, stimulating the expression of downstream cytoprotective enzymes such as HO-1 and NADPH quinone oxidoreductase 1 [107]. Biochanin A has a promising antioxidant potential to mitigate arsenic induced hepatotoxicity via up-regulating the antioxidant enzymes like glutathione, superoxide dismutase and catalase in rat livers [108]. Furthermore, biochanin A displayed DPPH free radical scavenging activity ( $IC_{50}=129.11\pm2.6$

µg/ml), NO radical scavenging activity ( $IC_{50}=60.76\pm5.3$  µg/ml), metal chelating activity ( $IC_{50}=112.62\pm6.12$  µg/ml) and LPO inhibitory activity ( $IC_{50}=58.66\pm3.4$  µg/ml) [109].

### **3.4 Neuroprotective activities**

Biochanin A mitigated the A $\beta$ 25-35-mediated cytotoxicity in PC12 cells via preventing caspase activation and mitochondrial dysfunction [19]. The anti-apoptotic properties of biochanin A have also been reported against L-glutamate-stimulated cytotoxicity in PC12 cells (Figure 5) [110].

Protective mechanism of biochanin A was also examined on LPS-induced damage in dopaminergic neurons both *in vitro* and *in vivo*. The result shows that biochanin A blocked the activation of microglia and loss of neurons while inhibited MDA (malondialdehyde) production and increased SOD (superoxide dismutase), NADPH oxidase and glutathione peroxidase (GPx) activities. Biochanin A also down-regulated NO, TNF- $\alpha$ , IL-1 $\beta$  levels while inhibited ROS production *in vitro* (Figure 5) [18, 111, 112]. Biochanin A displayed neuroprotective activities in cerebral ischemia or reperfusion models of male rats by reducing brain edema and infarct volume [113].

Interestingly, biochanin A considerably attenuated the depletion of striatal dopamine, elevated the glutathione content and reduced the MDA content in substantia nigra of neurochemical deficit model of female and male rats [114]. Biochanin A also subsequently reduced the phosphorylation of p38MAPK and superoxide formation in neurochemical deficit mice models [115]. Biochanin A was recognized as the most promising mediator of glutamate oxaloacetate transaminase (GOT) gene expression in neural cells. Biochanin A enhanced the mRNA and protein expression of GOT and protected against the cell death caused by glutamate *in vitro* [116].

### **3.5 Anti-microbial activities**

Microbial infections persisted to be major threat to human health worldwide in spite of increasing efforts in developing modern pharmacology [117]. Overreliance on anti-microbial medications to treat some infections caused by pathogens has led to increase resistance in various strains of microorganisms [118, 119]. Treatment of microbial infections with natural bioactive compounds is a traditionally employed practice [120]. Biochanin A inhibited the replication of the H5N1 virus, blocked the H5N1-induced activation of ERK1/2, Akt and NF- $\kappa$ B and virus-

induced production of IL-6/-8/-10 [17]. Biochanin A has been reported to possess anti-leishmanial property against promastigotes of *Leishmania chagasi* ( $EC_{50} = 18.96 \mu\text{g/ml}$ ) [20] and anti-bacterial activity against *C. pneumoniae* with  $IC_{50}$  value of  $12 \mu\text{M}$  [121]. Biochanin A has been reported to possess synergistic effect with ciprofloxacin on the efflux system of resistant strain of *Staphylococcus aureus*. At concentration of  $40 \mu\text{g/mL}$ , biochanin A reduced the MIC value of ciprofloxacin from  $64 \mu\text{g/mL}$  to  $8 \mu\text{g/mL}$  [122]. Biochanin A also displayed anti-microbial potential against eight *Clostridia* spp. [123]. Synergistic antimicrobial activity of biochanin A along with fluoroquinolones was also noticed against antibiotic-resistant *Ureaplasmas* spp. [124]. Biochanin A was investigated as mycobacterial efflux pump inhibitor (EPI) in *Mycobacterium smegmatis*. It exhibited better efflux pump blocking activity than other flavonoids such as luteolin and resveratrol [125].

### **3.6 Hepatoprotective activities**

Liver injuries or dysfunctions pose a serious threat to human health since times [126]. Approximately 2,50,000 new cases and 20,000 demises due to liver ailments have been reported yearly [127]. ROS-mediated stress is the root cause for the progression of various types of diseases in the liver. Hepatic dysfunctions are originated by several lethal agents including alcohol, viruses, chemically reactive metabolites or their bio-activated products. Although modern system of therapeutics has been established, still there is urgent need of bio safe hepatoprotective medications. So, NPs from medicinal herbs are considered to be effectual and safe for the cure of liver ailments [128].

Biochanin A has been reported for hepatoprotective effect in the carbon tetrachloride-mediated liver toxicity in rats that could be attributed to antioxidant, anti-inflammatory as well as immunomodulatory activities of biochanin A [21]. The hepatoprotective properties of biochanin A against arsenic-mediated hepatic injury were evaluated in rat models. Administration of biochanin A ( $20 \text{ mg/kg}$ ) decreased the arsenic-induced liver toxicity by activating GSH, SOD and catalases [108].

### **3.7 Miscellaneous biological activities**

Biochanin A provides effective photo-protection to skin and is a good ingredient for safety against the ultraviolet (UV) photo-damage [129]. It is also responsible for its physiological role in preventing the postmenopausal osteoporosis [130]. Biochanin A exerts anti-hypertensive

effects in ovariectomized rats [131]. The gastroprotective activity of this compound could be credited to improve cellular metabolic pathways e.g., increase in the actions of NO and SOD as well as increase in MDA levels and expression of Hsp70 [132]. Biochanin A has been reported for having potential anti-hyperglycemic action in streptozotocin mediated diabetic rats and its beneficial anti-diabetic effect has also been investigated in the male Wistar rats [26, 133]. In high-fat diet-stimulated hyperlipidemic mice, biochanin A decreased total cholesterol levels which gave new insights into the role of biochanin A as hypolipidemic agent [134]. Biochanin A has also been proved as an interesting agent for halting TCDD-stimulated wasting syndrome. Mechanism of action involves up-regulation in adipogenesis-linked factors like PPAR- $\gamma$  and adiponectin (which are reduced by TCDD) as well as prohibition of TCDD-mediated decrease in the formation of glucose transporter-4 and insulin receptor substrate 1, respectively [135]. Another study was conducted to unveil the biomimetic and lipophilic property of phytoestrogens including biochanin A. Results concluded that biochanin A along with other isoflavones possess high lipophilicity, AGP-binding and Caco-2 permeability [136]. Biochanin A might be beneficial as an alternative for estrogen therapy to improve cutaneous and renal changes in postmenopausal women [137].

#### **4. Bioavailability of biochanin A**

Bioavailability refers to the rate of absorption of drug at the site of drug action in systematic circulation. Several investigations have reported the bioavailability of flavones as <1%  $\mu\text{mol/L}$  after administration in the humans [138]. Drugs which have lower bioavailability are required to be administrated orally at a high dosage as only a limited portion of the drug is absorbed in systematic circulation [139, 140].

Bioavailability of biochanin A was recorded as 2.6% after oral administration of 5 mg/kg dose while 1.2% after oral administration of 50 mg/kg dose in rats. The free fraction of biochanin A in rat plasma was found to be 1.5%. The absorption of biochanin A was reported to be rapid because of high permeability of biochanin A, however, biliary elimination and extensive metabolism might be the major factors for its poor bioavailability [141]. While in case of simultaneous administration of five flavonoids to rats, bioavailability of biochanin A was found to be 21.3% which suggests that combination of flavonoids might have improved the bioavailability of biochanin A [142].

## 5. Structure –activity relationship of biochanin A

Isoflavonoids in comparison to isoflavone and isoflavanone exhibit good biological activities due to the structural modifications. Presence of 2, 3-double bond in ring C plays a vital role in biological activities of isoflavonoids. Biochanin A has 2, 3-double bond and 7-OH in ring A that increase the activity [143]. Intra isoflavonoid comparison showed that the DPPH radical scavenging activity of biochanin A (>100 %) is stronger than ascorbic acid (ascorbic acid 92.22% while biochanin A >100 %) [144]. The potent antioxidant potential of biochanin A is due to the presence of 7-OH in ring A and 4'-OCH<sub>3</sub> in ring B that greatly increase the antioxidant activity of biochanin A [145]. Different derivatives of biochanin A showed that the position-7 in ring A, position-4' in ring B and 2, 3-double bond in ring C are important in reactivity behavior. Free hydroxyl group at position-7 increases the antitumor activity while hydroxyl at position-5 decreases the antioxidant activity because it prevents the production of active radicals [146]. For example, esterification at 7-position in ring A enhanced the anti-proliferative activity against MCF-7 cells [57] (Figure 6).

## 6. Concluding remarks

At present, nature-derived bioactive compounds are gaining interest due to their pharmacological potential. In this article, we have highlighted the anticancer, antioxidant, anti-inflammatory, anti-microbial, and neuroprotective properties of biochanin A. Collected data from various researches have affirmed potent role of biochanin A in the treatment of several cancer types. Critical evaluation of reported researches has unveiled the fact that this isoflavone displays best potency towards breast cancerous cells with IC<sub>50</sub> 0.32  $\mu$ M. Thus, it would be worthwhile to examine about mechanism of action of biochanin A against breast cancer because this cancer type is most prevalent and lethal among the women. It would also be useful to explore the structural activity relationship of biochanin A by organic chemists to synthesize more bioavailable derivatives of biochanin A. Moreover, toxicological profiling of biochanin A such as hepatotoxicity and nephrotoxicity also needs to be explored. In the light of forerunner investigations, it could be hypothesized that biochanin A might serve as a novel and potential lead isoflavone for drug development but further research and preclinical studies are required to explore full range of its pharmacological properties.

## **Acknowledgments**

This study was supported by TWAS-COMSTECH Research Grant (No.\_17-180 RG/PHA/AS\_C), NRPUR Research Grants (8381/Punjab/NRPUR/R&D/HEC/2017, 8382/Punjab/NRPUR/R&D/HEC/2017) and ISESCO Research Grant (No. 3620). Moreover, we are highly obliged to HEC Pakistan for providing access to e-journals related to our study.

## **Conflicts of interest**

None.

## **Contribution of authors**

Ayesha Sarfraz and Maria Javeed made significant contribution in writing manuscript and designing figures of the manuscript. Azhar Rasul has made substantial contribution in designing and conceptualization the manuscript. Dr. Muhammad Ajmal Shah has proof read the article. Ghulam Hussain has contributed in acquisition of data. All authors have read and approved final manuscript.

## References

- [1] G. M. Cragg and D. J. Newman, "Natural products: a continuing source of novel drug leads," *Biochimica et biophysica acta*, vol. 1830, no. 6, pp. 3670-3695, 2013.
- [2] C. Veeresham, "Natural products derived from plants as a source of drugs," *J Adv Pharm Technol Res*, vol. 3, no. 4, pp. 200-201, 2012.
- [3] J. Hong, "Natural product synthesis at the interface of chemistry and biology," *Chemistry*, vol. 20, no. 33, pp. 10204-10212, 2014.
- [4] M. Zafar, I. Sarfraz, A. Rasul, F. Jabeen, K. Samiullah et al., "Tubeimoside-1, Triterpenoid Saponin, as a Potential Natural Cancer Killer " *Natural Product Communications*, vol. 13, no. 0, 2018.
- [5] D. J. Newman and G. M. Cragg, "Natural products as sources of new drugs over the 30 years from 1981 to 2010," *Journal of natural products*, vol. 75, no. 3, pp. 311-335, 2012.
- [6] P. Banerjee, J. Erehman, B. O. Gohlke, T. Wilhelm, R. Preissner et al., "Super Natural II- -a database of natural products," *Nucleic acids research*, vol. 43, no. Database issue, pp. D935-939, 2015.
- [7] A. Rasul, F. M. Millimouno, W. Ali Eltayb, M. Ali, J. Li et al., "Pinocembrin: a novel natural compound with versatile pharmacological and biological activities," *BioMed research international*, vol. 2013, no. pp. 379850, 2013.
- [8] C. Marucci, G. Fumagalli, F. Calogero, A. Silvani, M. S. Christodoulou et al., "Natural Products and Cancer Stem Cells," *Current pharmaceutical design*, vol. 21, no. 38, pp. 5547-5557, 2015.
- [9] A. Koeberle and O. Werz, "Multi-target approach for natural products in inflammation," *Drug discovery today*, vol. 19, no. 12, pp. 1871-1882, 2014.
- [10] C. Lopez-Alarcon and A. Denicola, "Evaluating the antioxidant capacity of natural products: a review on chemical and cellular-based assays," *Analytica chimica acta*, vol. 763, no. pp. 1-10, 2013.
- [11] A. A. Stromstedt, J. Felth and L. Bohlin, "Bioassays in natural product research - strategies and methods in the search for anti-inflammatory and antimicrobial activity," *Phytochemical analysis : PCA*, vol. 25, no. 1, pp. 13-28, 2014.



- [12] F. Mujeeb, P. Bajpai and N. Pathak, "Phytochemical evaluation, antimicrobial activity, and determination of bioactive components from leaves of *Aegle marmelos*," *BioMed research international*, vol. 2014, no. pp. 497606, 2014.
- [13] K. P. Ko, "Isoflavones: chemistry, analysis, functions and effects on health and cancer," *Asian Pacific journal of cancer prevention : APJCP*, vol. 15, no. 17, pp. 7001-7010, 2014.
- [14] I. Kaczmarczyk-Sedlak, M. Zych, W. Wojnar, E. Ozimina-Kaminska, S. Dudek et al., "Biochanin a Shows No Effect on Skeletal System in Ovariectomized Rats, When Administered in Moderate Dose," *Acta poloniae pharmaceutica*, vol. 72, no. 3, pp. 587-596, 2015.
- [15] A. Jain, J. C. Lai and A. Bhushan, "Biochanin A inhibits endothelial cell functions and proangiogenic pathways: implications in glioma therapy," *Anti-cancer drugs*, vol. 26, no. 3, pp. 323-330, 2015.
- [16] L. Kole, B. Giri, S. K. Manna, B. Pal and S. Ghosh, "Biochanin-A, an isoflavon, showed anti-proliferative and anti-inflammatory activities through the inhibition of iNOS expression, p38-MAPK and ATF-2 phosphorylation and blocking NFkappaB nuclear translocation," *European journal of pharmacology*, vol. 653, no. 1-3, pp. 8-15, 2011.
- [17] P. Sithisarn, M. Michaelis, M. Schubert-Zsilavecz and J. Cinatl, Jr., "Differential antiviral and anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1 influenza A virus-infected cells," *Antiviral research*, vol. 97, no. 1, pp. 41-48, 2013.
- [18] J. Wang, C. He, W. Y. Wu, F. Chen, Y. Y. Wu et al., "Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage and oxidative stress in a rat model of Parkinson's disease," *Pharmacology, biochemistry, and behavior*, vol. 138, no. pp. 96-103, 2015.
- [19] J. W. Tan and M. K. Kim, "Neuroprotective Effects of Biochanin A against beta-Amyloid-Induced Neurotoxicity in PC12 Cells via a Mitochondrial-Dependent Apoptosis Pathway," *Molecules*, vol. 21, no. 5, 2016.
- [20] P. Sartorelli, C. S. Carvalho, J. Q. Reimao, M. J. Ferreira and A. G. Tempone, "Antiparasitic activity of biochanin A, an isolated isoflavone from fruits of *Cassia fistula* (Leguminosae)," *Parasitology research*, vol. 104, no. 2, pp. 311-314, 2009.

- [21] R. M. Breikaa, M. M. Algandaby, E. El-Demerdash and A. B. Abdel-Naim, "Biochanin A protects against acute carbon tetrachloride-induced hepatotoxicity in rats," *Bioscience, biotechnology, and biochemistry*, vol. 77, no. 5, pp. 909-916, 2013.
- [22] S. Vlaisavljevic, B. Kaurinovic, M. Popovic, M. Djurendic-Brenesel, B. Vasiljevic et al., "Trifolium pratense L. as a potential natural antioxidant," *Molecules*, vol. 19, no. 1, pp. 713-725, 2014.
- [23] I. A. Kagan and M. D. Flythe, "Factors affecting the separation and bioactivity of red clover (*Trifolium pratense*) extracts assayed against *Clostridium sticklandii*, a ruminal hyper ammonia-producing bacterium," *Nat Prod Commun*, vol. 7, no. 12, pp. 1605-1608, 2012.
- [24] J. Chen, B. Ge, Y. Wang, Y. Ye, S. Zeng et al., "Biochanin A promotes proliferation that involves a feedback loop of microRNA-375 and estrogen receptor alpha in breast cancer cells," *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*, vol. 35, no. 2, pp. 639-646, 2015.
- [25] V. Chundi, S. R. Challa, D. R. Garikapati, G. Juvva, A. Jampani et al., "Biochanin-A attenuates neuropathic pain in diabetic rats," *Journal of Ayurveda and integrative medicine*, vol. 7, no. 4, pp. 231-237, 2016.
- [26] R. Harini, M. Ezhumalai and K. V. Pugalendi, "Antihyperglycemic effect of biochanin A, a soy isoflavone, on streptozotocin-diabetic rats," *European journal of pharmacology*, vol. 676, no. 1-3, pp. 89-94, 2012.
- [27] Y. C. Chukwumah, L. T. Walker, M. Verghese and S. Ogutu, "Effect of frequency and duration of ultrasonication on the extraction efficiency of selected isoflavones and trans-resveratrol from peanuts (*Arachis hypogaea*)," *Ultrasonics sonochemistry*, vol. 16, no. 2, pp. 293-299, 2009.
- [28] L. Zhang, Q. Li, X. Yang and Z. Xia, "Effects of sodium selenite and germination on the sprouting of chickpeas (*Cicer arietinum* L.) and its content of selenium, formononetin and biochanin A in the sprouts," *Biological trace element research*, vol. 146, no. 3, pp. 376-380, 2012.
- [29] V. Khedgikar, J. Gautam, P. Kushwaha, A. Kumar, G. K. Nagar et al., "A standardized phytopreparation from an Indian medicinal plant (*Dalbergia sissoo*) has antiresorptive

- and bone-forming effects on a postmenopausal osteoporosis model of rat," *Menopause*, vol. 19, no. 12, pp. 1336-1346, 2012.
- [30] X. Ming, M. Ding, B. Zhai, L. Xiao, T. Piao et al., "Biochanin A inhibits lipopolysaccharide-induced inflammation in human umbilical vein endothelial cells," *Life sciences*, vol. 136, no. pp. 36-41, 2015.
- [31] H. R. Lindner, "Occurrence of anabolic agents in plants and their importance," *Environmental quality and safety. Supplement*, vol. no. 5, pp. 151-158, 1976.
- [32] N. Lemežienė, A. Padarauskas, B. Butkutė, J. Cesevičienė, L. Taujenis et al., "The concentration of isoflavones in red clover (*Trifolium pratense* L.) at flowering stage@@@Izoflavonų koncentracija raudonojo dobilo (*Trifolium pratense* L.)," *Zemdirbyste-Agriculture* vol. 102, no. 4, pp. 443-448, 2015.
- [33] S. F. Farag, A. S. Ahmed, K. Terashima, Y. Takaya and M. Niwa, "Isoflavonoid glycosides from *Dalbergia sissoo*," *Phytochemistry*, vol. 57, no. 8, pp. 1263-1268, 2001.
- [34] Q. Lv, Y. Yang, Y. Zhao, D. Gu, D. He et al., "Comparative Study on Separation and Purification of Isoflavones from the Seeds and Sprouts of Chickpea by HSCCC," *Journal of liquid chromatography & related technologies*, vol. 32, no. 19, pp. 2879-2892, 2009.
- [35] Y. C. Chukwumah, L. T. Walker, M. Verghese, M. Bokanga, S. Ogutu et al., "Comparison of extraction methods for the quantification of selected phytochemicals in peanuts (*Arachis hypogaea*)," *Journal of agricultural and food chemistry*, vol. 55, no. 2, pp. 285-290, 2007.
- [36] N. L. Booth, C. R. Overk, P. Yao, S. Totura, Y. Deng et al., "Seasonal variation of red clover (*Trifolium pratense* L., Fabaceae) isoflavones and estrogenic activity," *Journal of agricultural and food chemistry*, vol. 54, no. 4, pp. 1277-1282, 2006.
- [37] E. Mohamed, S. AbouZid and A. Seida, "Phytochemical and Biological Studies on Isoflavonoids from *Dalbergia paniculata* Cultivated in Egypt," *Pharmacologia*, vol. 3, no. 3, pp. 84-90, 2012.
- [38] B. E. Deavours and R. A. Dixon, "Metabolic engineering of isoflavonoid biosynthesis in alfalfa," *Plant physiology*, vol. 138, no. 4, pp. 2245-2259, 2005.
- [39] K. S. Bora and A. Sharma, "Phytochemical and pharmacological potential of *Medicago sativa*: a review," *Pharmaceutical biology*, vol. 49, no. 2, pp. 211-220, 2011.

- [40] B. Butkute, A. Dagilyte, R. Benetis, A. Padarauskas, J. Ceseviciene et al., "Mineral and Phytochemical Profiles and Antioxidant Activity of Herbal Material from Two Temperate Astragalus Species," *BioMed research international*, vol. 2018, no. pp. 6318630, 2018.
- [41] I. Sarfraz, A. Rasul, F. Jabeen, T. Younis, M. K. Zahoor et al., "Fraxinus: A Plant with Versatile Pharmacological and Biological Activities," *Evidence-based complementary and alternative medicine : eCAM*, vol. 2017, no. pp. 4269868, 2017.
- [42] E. Rajesh, L. S. Sankari, L. Malathi and J. R. Krupaa, "Naturally occurring products in cancer therapy," *Journal of pharmacy & bioallied sciences*, vol. 7, no. Suppl 1, pp. S181-183, 2015.
- [43] H. Greenlee, "Natural products for cancer prevention," *Seminars in oncology nursing*, vol. 28, no. 1, pp. 29-44, 2012.
- [44] Y. N. Hsu, H. W. Shyu, T. W. Hu, J. P. Yeh, Y. W. Lin et al., "Anti-proliferative activity of biochanin A in human osteosarcoma cells via mitochondrial-involved apoptosis," *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*, vol. 112, no. pp. 194-204, 2018.
- [45] M. Sotak, A. Sumova and J. Pacha, "Cross-talk between the circadian clock and the cell cycle in cancer," *Annals of medicine*, vol. 46, no. 4, pp. 221-232, 2014.
- [46] K. Vermeulen, D. R. Van Bockstaele and Z. N. Berneman, "The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer," *Cell proliferation*, vol. 36, no. 3, pp. 131-149, 2003.
- [47] Z. Zhang, C. Z. Wang, G. J. Du, L. W. Qi, T. Calway et al., "Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells," *International journal of oncology*, vol. 43, no. 1, pp. 289-296, 2013.
- [48] Y. J. Seo, B. S. Kim, S. Y. Chun, Y. K. Park, K. S. Kang et al., "Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1," *Journal of Korean medical science*, vol. 26, no. 11, pp. 1489-1494, 2011.
- [49] L. Rice, V. G. Samed, T. A. Medrano, C. A. Sweeney, H. V. Baker et al., "Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts," *The Prostate*, vol. 52, no. 3, pp. 201-212, 2002.

- [50] M. M. Youssef, M. F. Tolba, N. N. Badawy, A. W. Liu, E. El-Ahwany et al., "Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells," *Scientific reports*, vol. 6, no. pp. 30717, 2016.
- [51] Y. Li, H. Yu, F. Han, M. Wang, Y. Luo et al., "Biochanin A Induces S Phase Arrest and Apoptosis in Lung Cancer Cells," *BioMed research international*, vol. 2018, no. pp. 3545376, 2018.
- [52] V. Desai, A. Jain, H. Shaghghi, R. Summer, J. C. K. Lai et al., "Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme," *Anticancer research*, vol. 39, no. 1, pp. 57-66, 2019.
- [53] T. G. Peterson, G. P. Ji, M. Kirk, L. Coward, C. N. Falany et al., "Metabolism of the isoflavones genistein and biochanin A in human breast cancer cell lines," *The American journal of clinical nutrition*, vol. 68, no. 6 Suppl, pp. 1505S-1511S, 1998.
- [54] E. H. Han, J. Y. Kim and H. G. Jeong, "Effect of biochanin A on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells," *Archives of pharmacal research*, vol. 29, no. 7, pp. 570-576, 2006.
- [55] Y. J. Moon, B. S. Shin, G. An and M. E. Morris, "Biochanin A inhibits breast cancer tumor growth in a murine xenograft model," *Pharmaceutical research*, vol. 25, no. 9, pp. 2158-2163, 2008.
- [56] S. I. Khan, J. Zhao, I. A. Khan, L. A. Walker and A. K. Dasmahapatra, "Potential utility of natural products as regulators of breast cancer-associated aromatase promoters," *Reproductive biology and endocrinology : RB&E*, vol. 9, no. pp. 91, 2011.
- [57] N. Fokialakis, X. Alexi, N. Aligiannis, D. Siriani, A. K. Meligova et al., "Ester and carbamate ester derivatives of Biochanin A: synthesis and in vitro evaluation of estrogenic and antiproliferative activities," *Bioorganic & medicinal chemistry*, vol. 20, no. 9, pp. 2962-2970, 2012.
- [58] V. Sehdev, J. C. Lai and A. Bhushan, "Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells," *Journal of oncology*, vol. 2009, no. pp. 121458, 2009.

- [59] Y. J. Moon, D. A. Brazeau and M. E. Morris, "Effects of flavonoids genistein and biochanin a on gene expression and their metabolism in human mammary cells," *Nutrition and cancer*, vol. 57, no. 1, pp. 48-58, 2007.
- [60] T. G. Peterson, L. Coward, M. Kirk, C. N. Falany and S. Barnes, "The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A," *Carcinogenesis*, vol. 17, no. 9, pp. 1861-1869, 1996.
- [61] Y. Wang, W. Man Gho, F. L. Chan, S. Chen and L. K. Leung, "The red clover (*Trifolium pratense*) isoflavone biochanin A inhibits aromatase activity and expression," *The British journal of nutrition*, vol. 99, no. 2, pp. 303-310, 2008.
- [62] T. Sehm, Z. Fan, R. Weiss, M. Schwarz, T. Engelhorn et al., "The impact of dietary isoflavonoids on malignant brain tumors," *Cancer medicine*, vol. 3, no. 4, pp. 865-877, 2014.
- [63] S. Puli, A. Jain, J. C. Lai and A. Bhushan, "Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells," *Neurochemical research*, vol. 35, no. 7, pp. 986-993, 2010.
- [64] S. Puli, J. C. Lai and A. Bhushan, "Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones," *Journal of neuro-oncology*, vol. 79, no. 2, pp. 135-142, 2006.
- [65] M. Michaelis, P. Sithisarn and J. Cinatl, Jr., "Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A," *BMC research notes*, vol. 7, no. pp. 384, 2014.
- [66] Y. Wang, J. J. Li and Y. M. Chen, "Biochanin A extirpates the epithelial-mesenchymal transition in a human lung cancer," *Experimental and therapeutic medicine*, vol. 15, no. 3, pp. 2830-2836, 2018.
- [67] S. Zhang, X. Yang and M. E. Morris, "Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport," *Molecular pharmacology*, vol. 65, no. 5, pp. 1208-1216, 2004.
- [68] M. J. Chung, J. K. Sohng, D. J. Choi and Y. I. Park, "Inhibitory effect of phloretin and biochanin A on IgE-mediated allergic responses in rat basophilic leukemia RBL-2H3 cells," *Life sciences*, vol. 93, no. 9-11, pp. 401-408, 2013.

- [69] M. C. Fung, Y. Y. Szeto, K. N. Leung, Y. L. Wong-Leung and N. K. Mak, "Effects of biochanin A on the growth and differentiation of myeloid leukemia WEHI-3B (JCS) cells," *Life sciences*, vol. 61, no. 2, pp. 105-115, 1997.
- [70] E. Szliszka, Z. P. Czuba, A. Mertas, A. Paradysz and W. Krol, "The dietary isoflavone biochanin-A sensitizes prostate cancer cells to TRAIL-induced apoptosis," *Urologic oncology*, vol. 31, no. 3, pp. 331-342, 2013.
- [71] G. Peterson and S. Barnes, "Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation," *The Prostate*, vol. 22, no. 4, pp. 335-345, 1993.
- [72] X. Y. Sun, C. A. Plouzek, J. P. Henry, T. T. Wang and J. M. Phang, "Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells," *Cancer research*, vol. 58, no. 11, pp. 2379-2384, 1998.
- [73] R. Kumar, V. Verma, A. Jain, R. K. Jain, J. P. Maikhuri et al., "Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer," *The Journal of nutritional biochemistry*, vol. 22, no. 8, pp. 723-731, 2011.
- [74] S. J. Su, N. H. Chow, M. L. Kung, T. C. Hung and K. L. Chang, "Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity," *Nutrition and cancer*, vol. 45, no. 1, pp. 113-123, 2003.
- [75] Y. J. Moon, S. Zhang, D. A. Brazeau and M. E. Morris, "Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells," *Molecular nutrition & food research*, vol. 51, no. 3, pp. 317-323, 2007.
- [76] K. Yanagihara, A. Ito, T. Toge and M. Numoto, "Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract," *Cancer research*, vol. 53, no. 23, pp. 5815-5821, 1993.
- [77] I. A. Cho, S. J. You, K. R. Kang, S. G. Kim, J. S. Oh et al., "Biochanin-A induces apoptosis and suppresses migration in FaDu human pharynx squamous carcinoma cells," *Oncology reports*, vol. 38, no. 5, pp. 2985-2992, 2017.

- [78] P. Xiao, B. Zheng, J. Sun and J. Yang, "Biochanin A induces anticancer effects in SK-Mel-28 human malignant melanoma cells via induction of apoptosis, inhibition of cell invasion and modulation of NF-kappaB and MAPK signaling pathways," *Oncology letters*, vol. 14, no. 5, pp. 5989-5993, 2017.
- [79] V. C. Lin, H. Y. Ding, P. C. Tsai, J. Y. Wu, Y. H. Lu et al., "In vitro and in vivo melanogenesis inhibition by biochanin A from *Trifolium pratense*," *Bioscience, biotechnology, and biochemistry*, vol. 75, no. 5, pp. 914-918, 2011.
- [80] V. Bhardwaj, S. M. Tadinada, A. Jain, V. Sehdev, C. K. Daniels et al., "Biochanin A reduces pancreatic cancer survival and progression," *Anti-cancer drugs*, vol. 25, no. 3, pp. 296-302, 2014.
- [81] J. T. Hsu, C. Ying and C. J. Chen, "Regulation of inducible nitric oxide synthase by dietary phytoestrogen in MCF-7 human mammary cancer cells," *Reproduction, nutrition, development*, vol. 40, no. 1, pp. 11-18, 2000.
- [82] Y. Zhao, L. Wang, X. Zhai, T. Cui, G. Wang et al., "The effect of biochanin A on cell growth, apoptosis, and migration in osteosarcoma cells," *Die Pharmazie*, vol. 73, no. 6, pp. 335-341, 2018.
- [83] Q. Luo, X. Shi, J. Ding, Z. Ma, X. Chen et al., "Network Pharmacology Integrated Molecular Docking Reveals the Antiosteosarcoma Mechanism of Biochanin A," *Evidence-based complementary and alternative medicine : eCAM*, vol. 2019, no. pp. 1410495, 2019.
- [84] C. Li, S. M. Hashimi, D. A. Good, S. Cao, W. Duan et al., "Apoptosis and microRNA aberrations in cancer," *Clinical and experimental pharmacology & physiology*, vol. 39, no. 8, pp. 739-746, 2012.
- [85] P. Ilmarinen, E. Moilanen and H. Kankaanranta, "Eosinophil intracellular signalling: apoptosis," *Methods in molecular biology*, vol. 1178, no. pp. 71-80, 2014.
- [86] Y. Fan and A. Bergmann, "Distinct mechanisms of apoptosis-induced compensatory proliferation in proliferating and differentiating tissues in the *Drosophila* eye," *Developmental cell*, vol. 14, no. 3, pp. 399-410, 2008.
- [87] S. Shimizu, "[Development of anti-cancer drugs mediated by apoptosis and autophagy]," *Nihon rinsho. Japanese journal of clinical medicine*, vol. 73, no. 8, pp. 1302-1307, 2015.



- [88] A. Rasul, B. Yu, L. Zhong, M. Khan, H. Yang et al., "Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy," *Oncology reports*, vol. 27, no. 5, pp. 1481-1487, 2012.
- [89] A. Rasul, J. Di, F. M. Millimouno, M. Malhi, I. Tsuji et al., "Reactive oxygen species mediate isoalantolactone-induced apoptosis in human prostate cancer cells," *Molecules*, vol. 18, no. 8, pp. 9382-9396, 2013.
- [90] A. Rasul, M. Khan, M. Ali, J. Li and X. Li, "Targeting apoptosis pathways in cancer with alantolactone and isoalantolactone," *TheScientificWorldJournal*, vol. 2013, no. pp. 248532, 2013.
- [91] A. Rasul, M. Khan, B. Yu, T. Ma and H. Yang, "Xanthoxyletin, a coumarin induces S phase arrest and apoptosis in human gastric adenocarcinoma SGC-7901 cells," *Asian Pacific journal of cancer prevention : APJCP*, vol. 12, no. 5, pp. 1219-1223, 2011.
- [92] T. L. Johnson, M. B. Lai, J. C. Lai and A. Bhushan, "Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A," *Evidence-based complementary and alternative medicine : eCAM*, vol. 7, no. 3, pp. 351-358, 2010.
- [93] S. C. Sun, "Non-canonical NF-kappaB signaling pathway," *Cell research*, vol. 21, no. 1, pp. 71-85, 2011.
- [94] K. Vazquez-Santillan, J. Melendez-Zajgla, L. Jimenez-Hernandez, G. Martinez-Ruiz and V. Maldonado, "NF-kappaB signaling in cancer stem cells: a promising therapeutic target?," *Cellular oncology*, vol. 38, no. 5, pp. 327-339, 2015.
- [95] M. Kolberg, I. Paur, T. R. Balstad, S. Pedersen, D. R. Jacobs, Jr. et al., "Plant extracts of spices and coffee synergistically dampen nuclear factor-kappaB in U937 cells," *Nutrition research*, vol. 33, no. 10, pp. 817-830, 2013.
- [96] Y. Sun, W. Z. Liu, T. Liu, X. Feng, N. Yang et al., "Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis," *Journal of receptor and signal transduction research*, vol. 35, no. 6, pp. 600-604, 2015.
- [97] G. L. Liu, H. J. Yang, B. Liu and T. Liu, "Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway," *Journal of cellular biochemistry*, vol. 118, no. 10, pp. 3424-3434, 2017.

- [98] L. Santarpia, S. M. Lippman and A. K. El-Naggar, "Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy," *Expert opinion on therapeutic targets*, vol. 16, no. 1, pp. 103-119, 2012.
- [99] Y. Wu, S. Antony, J. L. Meitzler and J. H. Doroshow, "Molecular mechanisms underlying chronic inflammation-associated cancers," *Cancer letters*, vol. 345, no. 2, pp. 164-173, 2014.
- [100] Y. Zhang and W. A. Chen, "Biochanin A inhibits lipopolysaccharide-induced inflammatory cytokines and mediators production in BV2 microglia," *Neurochemical research*, vol. 40, no. 1, pp. 165-171, 2015.
- [101] X. Liu, T. Wang, X. Liu, L. Cai, J. Qi et al., "Biochanin A protects lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation," *International immunopharmacology*, vol. 38, no. pp. 324-331, 2016.
- [102] J. S. Oh, I. A. Cho, K. R. Kang, J. S. You, S. J. Yu et al., "Biochanin-A antagonizes the interleukin-1beta-induced catabolic inflammation through the modulation of NFkappaB cellular signaling in primary rat chondrocytes," *Biochemical and biophysical research communications*, vol. 477, no. 4, pp. 723-730, 2016.
- [103] L. Qiu, B. Lin, Z. Lin, Y. Lin, M. Lin et al., "Biochanin A ameliorates the cytokine secretion profile of lipopolysaccharide-stimulated macrophages by a PPARgamma-dependent pathway," *Molecular medicine reports*, vol. 5, no. 1, pp. 217-222, 2012.
- [104] T. G. Lim, J. E. Kim, S. K. Jung, Y. Li, A. M. Bode et al., "MLK3 is a direct target of biochanin A, which plays a role in solar UV-induced COX-2 expression in human keratinocytes," *Biochemical pharmacology*, vol. 86, no. 7, pp. 896-903, 2013.
- [105] E. Possik and A. Pause, "Measuring oxidative stress resistance of *Caenorhabditis elegans* in 96-well microtiter plates," *Journal of visualized experiments : JoVE*, vol. no. 99, pp. e52746, 2015.
- [106] M. Hajrezaie, N. Salehen, H. Karimian, M. Zahedifard, K. Shams et al., "Biochanin a gastroprotective effects in ethanol-induced gastric mucosal ulceration in rats," *PloS one*, vol. 10, no. 3, pp. e0121529, 2015.

- [107] F. Liang, W. Cao, Y. Huang, Y. Fang, Y. Cheng et al., "Isoflavone biochanin A, a novel nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element activator, protects against oxidative damage in HepG2 cells," *BioFactors*, vol. no. 2019.
- [108] A. M. Jalaludeen, W. T. Ha, R. Lee, J. H. Kim, J. T. Do et al., "Biochanin A Ameliorates Arsenic-Induced Hepato- and Hematotoxicity in Rats," *Molecules*, vol. 21, no. 1, pp. 69, 2016.
- [109] S. Kumari, R. Elancheran, J. Kotoky and R. Devi, "Rapid screening and identification of phenolic antioxidants in *Hydrocotyle sibthorpioides* Lam. by UPLC-ESI-MS/MS," *Food chemistry*, vol. 203, no. pp. 521-529, 2016.
- [110] J. W. Tan, C. L. Tham, D. A. Israf, S. H. Lee and M. K. Kim, "Neuroprotective effects of biochanin A against glutamate-induced cytotoxicity in PC12 cells via apoptosis inhibition," *Neurochemical research*, vol. 38, no. 3, pp. 512-518, 2013.
- [111] J. Wang, W. Y. Wu, H. Huang, W. Z. Li, H. Q. Chen et al., "Biochanin A Protects Against Lipopolysaccharide-Induced Damage of Dopaminergic Neurons Both In Vivo and In Vitro via Inhibition of Microglial Activation," *Neurotoxicity research*, vol. 30, no. 3, pp. 486-498, 2016.
- [112] H. Q. Chen, Z. Y. Jin and G. H. Li, "Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation," *Neuroscience letters*, vol. 417, no. 2, pp. 112-117, 2007.
- [113] W. Wang, L. Tang, Y. Li and Y. Wang, "Biochanin A protects against focal cerebral ischemia/reperfusion in rats via inhibition of p38-mediated inflammatory responses," *Journal of the neurological sciences*, vol. 348, no. 1-2, pp. 121-125, 2015.
- [114] L. Yu, X. Wang, H. Chen, Z. Yan, M. Wang et al., "Neurochemical and Behavior Deficits in Rats with Iron and Rotenone Co-treatment: Role of Redox Imbalance and Neuroprotection by Biochanin A," *Frontiers in neuroscience*, vol. 11, no. pp. 657, 2017.
- [115] Y. Li, Y. Liu, Y. Xu, H. Chen, Z. Yan et al., "Aggravated behavioral and neurochemical deficits and redox imbalance in mice with enhanced neonatal iron intake: improvement by biochanin A and role of microglial p38 activation," *Nutritional neuroscience*, vol. no. pp. 1-12, 2019.

- [116] S. Khanna, R. Stewart, S. Gnyawali, H. Harris, M. Balch et al., "Phytoestrogen isoflavone intervention to engage the neuroprotective effect of glutamate oxaloacetate transaminase against stroke," *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, vol. 31, no. 10, pp. 4533-4544, 2017.
- [117] D. M. Morens and A. S. Fauci, "Emerging infectious diseases: threats to human health and global stability," *PLoS pathogens*, vol. 9, no. 7, pp. e1003467, 2013.
- [118] A. Teka, J. Rondevaldova, Z. Asfaw, S. Demissew, P. Van Damme et al., "In vitro antimicrobial activity of plants used in traditional medicine in Gurage and Silti Zones, south central Ethiopia," *BMC complementary and alternative medicine*, vol. 15, no. pp. 286, 2015.
- [119] J. Lakshmaiah Narayana and J. Y. Chen, "Antimicrobial peptides: Possible anti-infective agents," *Peptides*, vol. 72, no. pp. 88-94, 2015.
- [120] A. Geyid, D. Abebe, A. Debella, Z. Makonnen, F. Abera et al., "Screening of some medicinal plants of Ethiopia for their anti-microbial properties and chemical profiles," *Journal of ethnopharmacology*, vol. 97, no. 3, pp. 421-427, 2005.
- [121] L. Hanski, N. Genina, H. Uvell, K. Malinovskaja, A. Gylfe et al., "Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation," *PloS one*, vol. 9, no. 12, pp. e115115, 2014.
- [122] D. Zou, K. Xie, H. Wang, Y. Chen and M. Xie, "[Inhibitory effects of biochanin A on the efflux pump of methicillin-resistant Staphylococcus aureus (MRSA)]," *Wei sheng wu xue bao = Acta microbiologica Sinica*, vol. 54, no. 10, pp. 1204-1211, 2014.
- [123] O. Sklenickova, J. Flesar, L. Kokoska, E. Vlkova, K. Halamova et al., "Selective growth inhibitory effect of biochanin A against intestinal tract colonizing bacteria," *Molecules*, vol. 15, no. 3, pp. 1270-1279, 2010.
- [124] H. Jin, C. Qi, Y. Zou, Y. Kong, Z. Ruan et al., "Biochanin A partially restores the activity of ofloxacin and ciprofloxacin against topoisomerase IV mutation-associated fluoroquinolone-resistant Ureaplasma species," *Journal of medical microbiology*, vol. 66, no. 11, pp. 1545-1553, 2017.
- [125] D. Lechner, S. Gibbons and F. Bucar, "Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis," *The Journal of antimicrobial chemotherapy*, vol. 62, no. 2, pp. 345-348, 2008.

- [126] H. Shamsi-Baghbanan, A. Sharifian, S. Esmaeili and B. Minaei, "Hepatoprotective herbs, avicenna viewpoint," *Iranian Red Crescent medical journal*, vol. 16, no. 1, pp. e12313, 2014.
- [127] B. C. Joshi, A. Prakash and A. N. Kalia, "Hepatoprotective potential of antioxidant potent fraction from *Urtica dioica* Linn. (whole plant) in CCl<sub>4</sub> challenged rats," *Toxicology reports*, vol. 2, no. pp. 1101-1110, 2015.
- [128] S. Wu, Y. Yue, H. Tian, Z. Li, X. Li et al., "Carthamus red from *Carthamus tinctorius* L. exerts antioxidant and hepatoprotective effect against CCl<sub>4</sub>-induced liver damage in rats via the Nrf2 pathway," *Journal of ethnopharmacology*, vol. 148, no. 2, pp. 570-578, 2013.
- [129] J. Y. Lin, J. A. Tournas, J. A. Burch, N. A. Monteiro-Riviere and J. Zielinski, "Topical isoflavones provide effective photoprotection to skin," *Photodermatology, photoimmunology & photomedicine*, vol. 24, no. 2, pp. 61-66, 2008.
- [130] K. H. Lee and E. M. Choi, "Biochanin A stimulates osteoblastic differentiation and inhibits hydrogen peroxide-induced production of inflammatory mediators in MC3T3-E1 cells," *Biological & pharmaceutical bulletin*, vol. 28, no. 10, pp. 1948-1953, 2005.
- [131] C. Sachdeva, N. Mishra and S. Sharma, "Development and characterization of enteric-coated microparticles of biochanin A for their beneficial pharmacological potential in estrogen deficient-hypertension," *Drug delivery*, vol. 23, no. 6, pp. 2044-2057, 2016.
- [132] H. Lin, B. Kou, X. Li, Y. Wang, B. Ding et al., "Grating-based phase-contrast imaging of tumor angiogenesis in lung metastases," *PloS one*, vol. 10, no. 3, pp. e0121438, 2015.
- [133] R. Azizi, M. T. Goodarzi and Z. Salemi, "Effect of biochanin a on serum visfatin level of streptozocin-induced diabetic rats," *Iranian Red Crescent medical journal*, vol. 16, no. 9, pp. e15424, 2014.
- [134] Z. Xue, Q. Zhang, W. Yu, H. Wen, X. Hou et al., "Potential Lipid-Lowering Mechanisms of Biochanin A," *Journal of agricultural and food chemistry*, vol. 65, no. 19, pp. 3842-3850, 2017.
- [135] E. M. Choi, K. S. Suh, S. Y. Park, S. O. Chin, S. Y. Rhee et al., "Biochanin A prevents 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced adipocyte dysfunction in cultured 3T3-L1 cells," *Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering*, vol. 54, no. 9, pp. 865-873, 2019.

- [136] K. Lasic, A. Bokulic, A. Milic, B. Nigovic and A. Mornar, "Lipophilicity and bio-mimetic properties determination of phytoestrogens using ultra-high-performance liquid chromatography," *Biomedical chromatography : BMC*, vol. 33, no. 8, pp. e4551, 2019.
- [137] A. A. A. Galal, A. A. Mohamed, S. I. Khater and M. M. M. Metwally, "Beneficial role of biochanin A on cutaneous and renal tissues of ovariectomized rats treated with anastrozole," *Life sciences*, vol. 201, no. pp. 9-16, 2018.
- [138] S. Passamonti, M. Terdoslavich, R. Franca, A. Vanzo, F. Tramer et al., "Bioavailability of flavonoids: a review of their membrane transport and the function of bilitranslocase in animal and plant organisms," *Current drug metabolism*, vol. 10, no. 4, pp. 369-394, 2009.
- [139] B. Vranikova and J. Gajdziok, "[Bioavailability and factors influencing its rate]," *Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti*, vol. 64, no. 1-2, pp. 7-13,
- [140] R. Al-Kassas, M. Bansal and J. Shaw, "Nanosizing techniques for improving bioavailability of drugs," *Journal of controlled release : official journal of the Controlled Release Society*, vol. 260, no. pp. 202-212, 2017.
- [141] Y. J. Moon, K. Sagawa, K. Frederick, S. Zhang and M. E. Morris, "Pharmacokinetics and Bioavailability of the Isoflavone Biochanin A in Rats " *The AAPS Journal* vol. 8, no. 3, pp. E433-E442, 2006.
- [142] L. M. Mallis, A. B. Sarkahian, H. A. Harris, M. Y. Zhang and O. J. McConnell, "Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry," *Journal of chromatography. B, Analytical technologies in the biomedical and life sciences*, vol. 796, no. 1, pp. 71-86, 2003.
- [143] G. Castellano and F. Torrens, "Quantitative Structure-Antioxidant Activity Models of Isoflavonoids: A Theoretical Study," *International journal of molecular sciences*, vol. 16, no. pp. 12891-12906, 2015.
- [144] R. Huiskes, E. Y. Chao and T. E. Crippen, "Parametric analyses of pin-bone stresses in external fracture fixation devices," *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*, vol. 3, no. 3, pp. 341-349, 1985.

- [145] G. Castellano and F. Torrens, "Quantitative Structure-Antioxidant Activity Models of Isoflavonoids: A Theoretical Study," *International journal of molecular sciences*, vol. 16, no. 6, pp. 12891-12906, 2015.
- [146] P. Li, X. Shi, Y. Wei, L. Qin, W. Sun et al., "Synthesis and Biological Activity of Isoflavone Derivatives from Chickpea as Potent Anti-Diabetic Agents," *Molecules*, vol. 20, no. 9, pp. 17016-17040, 2015.